Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

902.71 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 543
Open 902.71
Bid (Size) 905.01 (1)
Ask (Size) 910.03 (1)
Prev. Close 902.71
Today's Range 902.71 - 902.71
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.
Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories. 
Via The Motley Fool
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
This drugmaker should have a basketful of growth drivers over the next decade. 
Via The Motley Fool

Performance

YTD
+52.43%
+52.43%
1 Month
+1.24%
+1.24%
3 Month
+4.36%
+4.36%
6 Month
+22.92%
+22.92%
1 Year
+51.57%
+51.57%

More News

Read More
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
AskSlim Market Week - Friday, Sept 6
Via Talk Markets
Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points
Via Benzinga
Innovent Bio hopes for plus-sized profits from obesity drug
Via Benzinga
Topics Retirement
Exposures Pension
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Via Benzinga
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
Via The Motley Fool
Shorting The Fatties
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Via Benzinga
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Via The Motley Fool
Why Walgreens Boots Alliance Fell Another 22% in August
Via The Motley Fool
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
Via Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Top Medical Stocks To Hedge Against The September Effect
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly Trades Near All-Time High: Check Out The IBD 50, Big Cap 20, Other Top Stock Lists
Via Investor's Business Daily
3 Big Winners From The Q2 Earnings Season: LLY, LMT, META
Via Talk Markets
Topics Stocks
Exposures US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Will September Bring A Rebound In Google Stock Amid New Antitrust Trial?
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.